Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proptosis Clear all
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

NCT05683496
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
lonigutamab, Placebo
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Jacksonville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818
View directory record Official record
Conditions
Graves Disease
Interventions
MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
Biological
Lead sponsor
Merida Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Hollywood, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

NCT06021054
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug (VRDN-001), Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

NCT07661056
View directory record Official record
Conditions
Graves Disease
Interventions
BHV-1300, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Burbank, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Active, not recruiting Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

NCT07369063
View directory record Official record
Conditions
Graves Disease, Graves' Disease, Hyperthyroidism
Interventions
Ergocalciferol 50,000 IU, Methimazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
9 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Suspended Phase 2 Interventional

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

NCT06240455
View directory record Official record
Conditions
Graves Disease
Interventions
WP1302, WP1302 placebo, methimazole
Drug · Combination Product
Lead sponsor
Worg Biotherapeutics Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Preoperative Corticosteroids in Autoimmune Thyroid Disease

NCT05435547
View directory record Official record
Conditions
Graves Disease, Hashimoto Disease
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Jul 22, 2026, 4:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

NCT06106828
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib for Thyroid Eye Disease

NCT02845336
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Celecoxib, artificial tears
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy

NCT02205801
View directory record Official record
Conditions
Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions
Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )

NCT05176639
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
29
States / cities
Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Enrolling by invitation Phase 2 Interventional

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
89
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting No phase listed Observational

Evaluating an AI Tool for Detecting Thyrotoxic States

NCT07017907
View directory record Official record
Conditions
Graves Disease, Hyperthyroidism/Thyrotoxicosis
Interventions
Heart rate-based AI software for detecting thyrotoxicosis
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

NCT06179875
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

NCT05517421
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Batoclimab, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

NCT06275373
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
Interventions
Teprotumumab Injection [Tepezza]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 2Phase 3 Interventional

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
linsitinib
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Miami, Florida • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

NCT03461211
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 22, 2026, 4:13 PM EDT
Terminated No phase listed Observational

Efficacy of Methimazole Dosing Algorithm

NCT05964452
View directory record Official record
Conditions
Graves Disease
Interventions
Methimazole Tablets
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 4:13 PM EDT